GlucoTrack, Inc. (GCTK) Dividend History

Company News

• Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights

  Glucotrack, a medical technology company, reported strong progress in 2024, including advancing its continuous blood glucose monitoring technology from preclinical to clinical stage, strengthening its leadership team, and securing funding to support its growth plans.

  GlobeNewswire Inc.
• Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer

  Glucotrack, a medical technology company, has appointed industry veteran Peter C. Wulff as its new Chief Financial Officer. Wulff has over 35 years of financial management experience and will play a key role in the commercialization of Glucotrack's continuous blood glucose monitoring system for people with diabetes.

  GlobeNewswire Inc.
• GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS

  Diabetes industry veteran joins Glucotrack’s Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes

  GlobeNewswire Inc.
• GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR

  Completion of the novel epidural continuous glucose monitoring study confirms its potential for providing simplified disease management for patients with painful diabetic neuropathy

  GlobeNewswire Inc.
• GLUCOTRACK TO PRESENT IN THE JUNE 2024 SIDOTI SMALL CAP CONFERENCE

  Rutherford, NJ, June 10, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the Sidoti Small Cap Investor Conference.

  GlobeNewswire Inc.